oxycodone controlled release / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxycodone controlled release / Generic mfg.
NCT05265052: 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Not yet recruiting
2a/2b
177
NA
3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa), 3D1002 monotherapy (Phase IIb), OxyContin monotherapy (Phase IIb), 3D1002 + OxyContin (Phase IIb)
3D Medicines
Cancer Pain
06/25
09/25

Download Options